CHRS stock icon

Coherus BioSciences
CHRS

$1.88
1.05%
 

About: Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Employees: 306

0
Funds holding %
of 6,665 funds
0
Analysts bullish %
of 10 analysts
0
News positive %
of 8 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.31% less ownership

Funds ownership: 73.63% [Q4 2023] → 73.32% (-0.31%) [Q1 2024]

14% less funds holding

Funds holding: 155 [Q4 2023] → 134 (-21) [Q1 2024]

28% less call options, than puts

Call options by funds: $440K | Put options by funds: $609K

28% less capital invested

Capital invested by funds: $271M [Q4 2023] → $195M (-$75.3M) [Q1 2024]

31% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 55

49% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 43

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7
272%
upside
Avg. target
$11
485%
upside
High target
$13
591%
upside

10 analyst ratings

10 positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Douglas Tsao
538%upside
$12
Buy
Reiterated
24 May 2024
Truist Securities
Robyn Karnauskas
272%upside
$7
Buy
Maintained
13 May 2024
HC Wainwright & Co.
Douglas Tsao
538%upside
$12
Buy
Maintained
10 May 2024
HC Wainwright & Co.
Douglas Tsao
485%upside
$11
Buy
Maintained
20 Mar 2024
HC Wainwright & Co.
Douglas Tsao
591%upside
$13
Buy
Reiterated
14 Mar 2024

Financial journalist opinion

Based on 8 articles about CHRS published over the past 30 days